Total: $63.26M | ||||
Company | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; |
| ||||
Advanced | Private placement of subordinated convertible notes | N/A | $3.7 | Advanced Biotherapy raised about $3.7M through a private placement of notes (6/17) |
Bavarian Nordic | Private placement of common stock | 0.96S | DKK67 (US$8.8) | Bavarian Nordic raised US$8.8M when the subscription of shares in its rights issue closed; a total of 959,140 new shares were subscribed to at DKK70 per share (6/25) |
Celsion Corp. | Private placement of units | 0.002U | $2 | Celsion placed 2,000 units at $1,000 per unit, raising $2M; each unit consists of one share of its 8 percent Series B convertible preferred stock and a warrant to acquire 600 shares of Celsion common stock exercisable at 65 cents per share (6/3) |
CollaGenex Pharmaceuticals | Private placement of common stock | 0.032S | $0.27 | CollaGenex raised $266,667 with the second drawdown of an equity line with Kingsbridge Capital Ltd. (6/28) |
Cytogen Corp. | Private placement of common stock | 4.2S | $5 | Cytogen raised $5M in a private placement with the State of Wisconsin Investment Board (6/5) |
Helix BioMedix | Private placement of promissory notes | N/A | $3 | Helix raised $3M in the private financing (6/12) |
NeoTherapeutics | Private placement of common stock and warrants | 6.7S and 0.2W | $1.66 | NeoTherapeutics raised $1.66M through the sale of common stock and warrants to three institutional investors (6/12) |
Novavax Inc. | Private placement of a convertible note | N/A | $10 | Novavax raised $10M through the sale of a convertible note to King Pharmaceuticals Inc. (6/27) |
Pharsight Corp. | Private placement of common stock | N/A | $3.1 | Pharsight raised $3.1M in the first round of a two-round financing for $7.5M total; investors were the Sprout Group and Alloy Ventures (6/27) |
ProMetic Life | Private placement of common stock | 0.37S | C$1 (US | ProMetic raised about US$650,000 in a private placement of 370,371 shares (6/17) |
ReGen | Private placement of common stock | N/A | 0.43 (US | ReGen completed an interim funding round, raising US$634,000 from certain existing share- holders (6/19**) |
Synthetic Blood International Inc. (OTC BB:SYBD) | Equity line | N/A |
| Synthetic Blood secured a three-year, $20M equity line through Dutchess Private Equities Fund (6/3) |
SciClone Pharmaceuticals | Private placement of common stock | 4.09S | $10.62 | SciClone placed $10.62M in stock with institutional investors; A.G. Edwards & Sons acted as placement agent (6/14) |
Trinity Medical | Private placement of common stock | 3.8S | $0.19 | Trinity Medical raised $190,000 through the sale of common stock to accredited investors (6/7) |
Viventia Biotech | Private placement of convertible secured debentures | N/A | C$6 (US | Viventia completed a private placement of three convertible secured debentures for gross proceeds of US$3.9M; all three were sold to units of the Dan family, which owns about 81.5% of Viventia (6/25) |
YM BioSciences | Private placement of common stock as part of an initial public offering | 3.75S | C$15 (US | YM BioSciences raised C$15M in an initial public offering conducted through the placement of 3.75M shares with institutional and other investors; Canaccord Capital is the company's adviser and broker (6/12) |
| ||||
Notes: |
||||
This chart does not include real estate or manufacturing plant financings. |
||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. |
||||
@ Dates refer to the date of the press release. |
||||
** Denotes the date the item ran in BioWorld International. |
||||
N/A = Not available, applicable or reported. |
||||
AIM =Alternative Investment Market of the London Stock Exchange; AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange |